Highlights
In the efficacy population of the CART19-BE-02 trial, 84.4% of patients (27 of 32) achieved a complete response with undetected measurable residual disease (MRD) by day 28, utilizing a sensitivity threshold of 10^-5.
The study employed a fractionated intra-patient dose escalation (0.1, 0.3, 0.6, and 2.0 × 10^6 CAR T cells/kg), which proved instrumental in maintaining high therapeutic activity while mitigating acute toxicities.
